Dear E, Following a highly successful event last year, the 4th FierceBiotech Drug Development Forum will provide valuable insights from both buy-side and sell-side perspectives on how to successfully navigate the deal-making landscape. This year’s program will also showcase strategic considerations from biotech and mid-sized and big pharma leadership on how to ensure the successful development and commercialization of new products. |
|
|
| Featured Sessions for 2019 Uncertainty, Challenges, and Implications of Today’s Reimbursement Environment on the Deal-Making Landscape and Beyond |
|
|
| Kristen B. Slaoui, Ph.D.,
Vice President, Head of Business Development, Pharmaceuticals Commercial Portfolio, GLAXOSMITHKLINE |
| Tim Mayleben,
President and CEO, ESPERION THERAPEUTICS |
|
|
| New Indications in the Approval of Medicines |
|
|
David Weinreich, M.D.,
Senior Vice President, Head, Global Clinical Development, REGENERON |
| Robert Paul, M.D., Ph.D.,
Chief Medical Officer, ALECTOR |
|
|
| Key Questions Small Companies Should Ask When Evaluating Potential Partners |
|
|
Robert Bagdorf, M.D., MBA,
Group Lead, Search and Evaluation, Worldwide Business Development, PFIZER |
| Thomas Neenan,
CEO, ABFERO PHARMACEUTICALS |
| Albert Hsia, Ph.D.,
Executive Director, Business Development, MERCK & CO. |
| Gil Labrucherie,
Senior Vice President and Chief Financial Officer, NEKTAR THERAPEUTICS |
|
|
| Explore Innovative Endpoint Design to Maximize Impact on Patients and Payers |
|
|
| | Jim Doherty Chief Research Officer, SAGE THERAPEUTICS |
|
|
| Thank you to our 2019 sponsors! |
|
|
|
